Vitamin D supplementation does not change expression of circulating human leucocyte.

MASTAGLIA SR; BRYK G; MAROTTE C; SOMOZA J; BRITO GM; SEIJO M; FORNARI MC; DIEZ RA; OLIVERI B

Otro; XVIII Reunión Anual Asociación Argentina de Osteología y Metabolismo Mineral; 2011

The antimicrobial peptide cathelicidin (hCAP18) is synthesized in several cell types of the system immune, and 1,25(OH)2D is a direct inducer of its gene. The aim of this study was to evaluate the expression of leukocytes’ cathelicidin in 33 young healthy volunteers supplemented with vitamin D2, D3 or placebo (Pl) for 21days(d), allocated to the groups: GD2 (n=11); GD3 (n=11) and Pl (n=11). They received at baseline (b) 100,000 IU/d and from 7th to 21st, 4,800 IU/d of the corresponding D2/D3/Pl. At b and d 7th and 21st blood samples were obtained to measure 25OHD (RIA-DIASORIN) and the expression of hCAP18 in peripheral blood neutrophils (PMN), monocyte (MO) and lynfocyte (LI). This was assessed by flow cytometry with a FACSort® (Becton-Dickinson,USA) and the CellQuest® software (Becton-Dickinson), using the mouse monoclonal antibody OSX12 (Abcam, UK) specific for hCAP18, and a secondary incubation with FITC anti-murine IgG. Region corresponding to PMN, MO, LI was defined by side and forward scattering and the higher level of hCAP18 were identified in the fluorescence histogram of the region of PMN, MO, LI defined as M1. Statistical analysis: SPSS 19-USA. No significant differences were observed among the three groups in the expression hCAP18 in PMN, MO and LI either as level of expression (mean fluorescence) or as % of cells over-expressing it, in spite of the significant increment of 25OHD levels (≈100%) in both D groups. Under these experimental conditions, circulating human leucocyte‘s cathelicidin is not modified by vitamin D supplementation, independently of calciferol used. Grant: ANPCyT (PICT523), CONICET (PIP 0290)